HC Wainwright Reduces Earnings Estimates for Innate Pharma

Innate Pharma S.A. (NASDAQ:IPHA - Free Report) - Equities research analysts at HC Wainwright dropped their FY2028 earnings estimates for Innate Pharma in a research report issued on Thursday, April 24th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.11) per share for the year, down from their prior estimate of ($0.08). HC Wainwright currently has a "Buy" rating and a $11.00 price target on the stock.

Innate Pharma Price Performance

Shares of IPHA traded up $0.04 during midday trading on Monday, hitting $2.25. The company had a trading volume of 1,641 shares, compared to its average volume of 184,078. The company's 50 day moving average price is $1.98 and its 200 day moving average price is $1.89. Innate Pharma has a 52 week low of $1.29 and a 52 week high of $3.51.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.